These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14750218)

  • 21. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
    Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
    Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract]   [Full Text] [Related]  

  • 23. New dopamine agonists on the horizon.
    Heins JR
    S D J Med; 1997 Jul; 50(7):239-40. PubMed ID: 9240032
    [No Abstract]   [Full Text] [Related]  

  • 24. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. REAL and CALM: what have we learned?
    Morrish PK
    Mov Disord; 2003 Jul; 18(7):839-40. PubMed ID: 12815670
    [No Abstract]   [Full Text] [Related]  

  • 26. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 28. The initial treatment of Parkinson's disease should begin with levodopa.
    Weiner WJ
    Mov Disord; 1999 Sep; 14(5):716-24. PubMed ID: 10495031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
    Fanciulli A; Misasi R; Campanelli D; Buttarelli FR; Pontieri FR
    Pharmacol Rep; 2011; 63(4):1056-60. PubMed ID: 22001994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 31. Dopamine agonists.
    Factor SA
    Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
    Arai H; Minami J
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):313-9. PubMed ID: 17938518
    [No Abstract]   [Full Text] [Related]  

  • 34. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL; Rascol O; Senard JM
    Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved].
    MMW Fortschr Med; 2002 May; Suppl 2():88. PubMed ID: 12070869
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuroprotection in idiopathic Parkinson's disease.
    Reichmann H
    J Neurol; 2002 Oct; 249 Suppl 3():III/21-3. PubMed ID: 12522567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.